Literature DB >> 17855077

Palliation of advanced thyroid malignancies.

David Yü Greenblatt1, Herbert Chen.   

Abstract

While most thyroid cancers are slow-growing and have an excellent prognosis after appropriate treatment, a subset of thyroid cancers behave aggressively, and approximately 1500 individuals in the US will die of the disease in the year 2007. Advanced thyroid malignancies can cause distressing and life-threatening symptoms by local invasion in the neck, growth of distant metastases in the lung, bone, and other organs, and tumor production of bioactive substances in the case of medullary thyroid cancer. This article will review palliative modalities, including surgery, radioactive iodine, external beam radiation, and chemotherapy, as well as novel targeted therapies, for the treatment of patients with advanced thyroid malignancies.

Entities:  

Mesh:

Year:  2007        PMID: 17855077     DOI: 10.1016/j.suronc.2007.08.006

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  9 in total

1.  Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer.

Authors:  Mackenzie Cook; Xiao-Min Yu; Herbert Chen
Journal:  Am J Transl Res       Date:  2010-02-10       Impact factor: 4.060

2.  Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.

Authors:  Joel T Adler; Daniel G Hottinger; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Surg Res       Date:  2008-09-04       Impact factor: 2.192

3.  Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta.

Authors:  Joel T Adler; Mackenzie Cook; Yinggang Luo; Susan C Pitt; Jianhua Ju; Wenli Li; Ben Shen; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

4.  Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.

Authors:  David Yu Greenblatt; Max A Cayo; Joel T Adler; Li Ning; Megan R Haymart; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg       Date:  2008-06       Impact factor: 12.969

5.  Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival.

Authors:  Kevin Shepet; Amal Alhefdhi; Ngan Lai; Haggi Mazeh; Rebecca Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2012-11-29       Impact factor: 5.344

Review 6.  Notch Signaling in Thyroid Cancer.

Authors:  Rachael Guenter; Zeelu Patel; Herbert Chen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer.

Authors:  Gabriel Tremblay; Christopher Livings; Lydia Crowe; Venediktos Kapetanakis; Andrew Briggs
Journal:  Clinicoecon Outcomes Res       Date:  2016-06-30

8.  Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.

Authors:  Monika Wagner; Hanane Khoury; Liga Bennetts; Patrizia Berto; Jenifer Ehreth; Xavier Badia; Mireille Goetghebeur
Journal:  BMC Cancer       Date:  2017-04-17       Impact factor: 4.430

9.  Palliative and end of life care issues of carcinoma thyroid patient.

Authors:  Alka Goyal; Rahul Gupta; Syed Mehmood; Svs Deo; Seema Mishra; Sushma Bhatnagar
Journal:  Indian J Palliat Care       Date:  2012-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.